Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs

International Journal of Pharmaceutics

Volumn 129, Issue 1-2, 1996, Pages 203-210

  Beall, Howard D ^a,b   Sloan, Kenneth B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

1 alkylcarbonyl 5 FU; Diffusion cell; Flux; Partition coefficients; Skin accumulation; Solubility parameters; Water and lipid solubility

Indexed keywords

FLUOROURACIL; FLUOROURACIL DERIVATIVE; PRODRUG;

ANIMAL TISSUE; ARTICLE; DIFFUSION; DRUG SOLUBILITY; HYDROLYSIS; LIPID SOLUBILITY; MOUSE; NONHUMAN; NUDE MOUSE; PARTITION COEFFICIENT; PRIORITY JOURNAL; SKIN PENETRATION;

EID: 0030005178     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04327-6     Document Type: Article

References (17)

1. Beall, H.D., Bioreversible Derivatives of 5-Fluorouracil (5-FU): Improving Dermal and Transdermal Delivery with Prodrugs, Ph.D. dissertation, University of Florida, Gainesville, Dec. 1991.
2. Beall, H.D., Getz, J.J. and Sloan, K.B., The estimation of relative water solubility for prodrugs that are unstable in water. Int. J. Pharm., 93 (1993) 37-47.
3. Beall, H., Prankerd, R. and Sloan, K.B., Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm., 111 (1994) 223-233.
4. Beall, H., Prankerd, R. and Sloan, K.B., 1-Alkylcarbonyl-5-fluorouracil prodrugs: synthesis, thermal and hydrolytic stability. Drug Dev. Ind. Pharm., 22 (1996) 85-90.
5. Buur, A. and Bundgaard, H., Prodrugs of 5-fluorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil. Int. J. Pharm., 21 (1984) 349-364.
6. Buur, A. and Bundgaard, H., Prodrugs of 5-fluorouracil. V. 1-Alkyloxycarbonyl derivatives as potential prodrug forms for improved rectal or oral delivery of 5-fluorouracil. J. Pharm. Sci., 74 (1986) 522-527.
7. Epstein, E., Fluorouracil paste treatment of thin basal cell carcinomas. Arch. Dermatol., 121 (1985) 207-213.
8. Fedors, R.F., A method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci., 14 (1974) 147-154.
9. Martin, A., Wu, P.L. and Velasquez, T., Extended Hildebrand solubility approach: sulfonamides in binary and ternary solvents. J. Pharm. Sci., 74 (1985) 277-282.
10. Mollgaard, B., Hoelgaard, A. and Bundgaard, H., Pro-drugs as drug delivery systems. XXIII. Improved dermal delivery of 5-fluorouracil through human skin via N-acyloxymethyl pro-drug derivatives. Int. J. Pharm., 12 (1982) 153-162.
11. Sloan, K.B., Koch, S.A.M.. Siver, K.G. and Flowers, F.P., The use of solubility parameters of drug and vehicle to predict flux. J. Invest. Dermatol., 87 (1986) 244-252.
12. Sloan, K.B., Sherertz, E.F. and McTiernan, R.G., The effect of structure of Mannich base prodrugs on their ability to deliver theophylline and 5-fluorouracil through hairless mouse skin. Int. J. Pharm., 44 (1988) 87-96.
13. Sloan, K.B., Sherertz, E.F. and McTiernan, R.G., The effect of 5-fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5-FU. Arch. Dermatol. Res., 282 (1990) 484-486.
14. Sloan, K.B., Beall, H.D., Weimar, W.R. and Villaneuva, R., The effect of receptor phase composition on the permeability of hairless mouse skin in diffusion cell experiments. Int. J. Pharm., 73 (1991) 97-104.
15. Sloan, K.B., Functional group considerations in the development of prodrug approaches to solving topical delivery problems. In Sloan, K.B. (Ed.), Prodrugs: Topical and Ocular Drug Delivery, Marcel Dekker, New York, NY, 1992, pp. 17-116.
16. Sloan, K.B., Getz, J.J., Beall, H.D. and Prankerd, R.J., Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylaminocarbonyl-5-FU prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm., 93 (1993) 27-36.
17. Tsuji, T. and Sugai, T., Topically administered fluorouracil in psoriasis. Arch. Dermatol., 105 (1972) 208-212.